Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

Inclusion Criteria:

• Sinonasal inflammation for greater than 12 weeks which include at least 2 of thefollowing symptoms: nasal obstruction/congestion, nasal discharge (anterior orposterior), facial pressure/pain, reduction of sense of smell

• Confirmation of the clinical symptoms by (2a) CT scan evidence of paranasal sinusmucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from thesinuses or ostiomeatal complex

• Presence of nasal polyps seen on endoscopic exam or sinus CT scan

• Adults from age of 18-100 will be eligible

• All potential participants will be required to sign an Institutional Review Board (IRB) approved research consent form.

Exclusion Criteria:

• Children under the age of 18 will be excluded

• No pregnant or lactating females, prisoners, mentally disabled, or persons unable togive informed consent will be contemplated for inclusion.

• The subject groups will also exclude those with disease secondary to a clearlydefined anatomic process, such as facial trauma, and obstruction due to sinonasalneoplasm.

• To eliminate confounding variables in our ex vivo experimental studies, any subjectwith a history of exposure to oral or systemic IV glucocorticoids within 2 weeks ofsurgery or any immunomodulatory biologics will be excluded. These include, but arenot limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab,benralizumab, reslizumab, or rituximab.